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IMPORTANCE Achieving glycemic control remains a challenge for patients with type 2
diabetes, even with insulin therapy.
OBJECTIVE To assess whether a fixed ratio of insulin degludec/liraglutide was noninferior to
continued titration of insulin glargine in patients with uncontrolled type 2 diabetes treated
with insulin glargine andmetformin.
DESIGN, SETTING, AND PARTICIPANTS Phase 3,multinational, multicenter, 26-week,
randomized, open-label, 2-group, treat-to-target trial conducted at 75 centers in 10 countries
from September 2013 to November 2014 among 557 patients with uncontrolled diabetes
treated with glargine (20-50 U) andmetformin (1500mg/d) with glycated hemoglobin
(HbA1c) levels of 7% to 10% and a bodymass index of 40 or lower.
INTERVENTIONS 1:1 randomization to degludec/liraglutide (n = 278; maximum dose, 50 U of
degludec/1.8 mg of liraglutide) or glargine (n = 279; nomaximum dose), with twice-weekly
titration to a glucose target of 72 to 90mg/dL.
MAIN OUTCOMES ANDMEASURES Primary outcomemeasure was change in HbA1c level after
26 weeks, with a noninferiority margin of 0.3% (upper bound of 95% CI, <0.3%). If
noninferiority of degludec/liraglutide was achieved, secondary end points were tested for
statistical superiority and included change in HbA1c level, change in body weight, and rate of
confirmed hypoglycemic episodes.
RESULTS Among557 randomizedpatients (mean: age, 58.8 years;women,49.7%), 92.5%
ofpatients completed the trial andprovideddata at 26weeks. BaselineHbA1c levelwas8.4%
for thedegludec/liraglutide groupand8.2%for theglarginegroup.HbA1c level reductionwas
greaterwithdegludec/liraglutide vs glargine (−1.81% for thedegludec/liraglutide groupvs−1.13%
for theglarginegroup; estimated treatmentdifference [ETD], –0.59%[95%CI, –0.74%to
–0.45%]),meeting criteria for noninferiority (P < .001), andalsomeeting criteria for statistical
superiority (P < .001). Treatmentwithdegludec/liraglutidewas also associatedwithweight loss
comparedwithweight gainwith glargine (–1.4 kg for degludec/liraglutide vs 1.8 kg for glargine;
ETD, –3.20kg [95%CI, –3.77 to –2.64],P < .001) and fewer confirmedhypoglycemic episodes
(episodes/patient-year exposure, 2.23 for degludec/liraglutide vs 5.05 for glargine; estimated rate
ratio,0.43 [95%CI,0.30 to0.61],P < .001).Overall and serious adverse event rateswere similar
in the2groups, except formorenonserious gastrointestinal adverse events reportedwith
degludec/liraglutide (adverse events, 79 for degludec/liraglutide vs 18 for glargine).
CONCLUSIONS AND RELEVANCE Among patients with uncontrolled type 2 diabetes taking
glargine andmetformin, treatment with degludec/liraglutide compared with up-titration of
glargine resulted in noninferior HbA1c levels, with secondary analyses indicating greater HbA1c
level reduction after 26 weeks of treatment. Further studies are needed to assess longer-term
efficacy and safety.
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A chieving optimal glucose control is a challenge for themajorityofpatientswith type2diabetes,with less thanone-third of patients treatedwith basal insulin reach-
ing a glycatedhemoglobin (HbA1c) level of less than7.0%.1De-
spite this,manypatients continuebasal insulinwithout treat-
ment intensification.2 Traditionally, such patients and their
clinicians intensify the insulin regimen, generally by further
up-titrationof thebasal in-
sulin dose or with the ad-
dition of 1 or more meal-
time insulin injections.
Both options increase the
risk of hypoglycemia and
weight gain. In addition,
there may be a practical
limit to the glucose-lowering efficacy achievablewith insulin
titration alone, irrespective of the regimen. Recently, combi-
nationsofglucagon-likepeptide-1 receptoragonists (GLP-1RAs)
and basal insulin have been recommended as an alternative
in international guidelines, extending the intensification op-
tions available.3
In this trial, we addressed the practical and patient-
centered question of the relative efficacy and safety of opti-
mizedandunlimited titrationof aonce-daily injectionofbasal
insulin (glargine) vs a once-daily injection of the fixed-ratio
combinationof basal insulindegludec (dose limit of 50U) and
the GLP-1RA liraglutide (dose limit of 1.8 mg) (hereafter re-
ferred toasdegludec/liraglutide).Althoughcomparisonsofde-
gludec/liraglutide tomore complex insulin regimensarebeing
studied in an ongoing trial,4 the use of basal insulin in combi-
nationwith oral agents is thedominant treatment strategy for
refractory hyperglycemia and the most relevant comparator
for clinicians.
Theprimaryobjectiveof this trialwastodeterminewhether
degludec/liraglutidewasnoninferior toup-titrationofglargine
in change from baseline in HbA1c level in patients with uncon-
trolled type 2 diabetes treatedwith glargine andmetformin. If
theprimaryobjectivewasmet, secondaryobjectiveswere toas-
sesswhetherdegludec/liraglutidewasstatisticallysuperiorcom-
paredwithglargine inchangefrombaselineofHbA1c level,body
weight, and rate of confirmed hypoglycemia.
Methods
The trial was reviewed and approved by institutional review
boards,andallpatientsprovidedwritten,informedconsentforms
prior toparticipation.DUALVwasaphase3,multinational,mul-
ticenter, randomized clinical trial conducted from September
2013 toNovember2014witha total lengthof29weeks (2weeks
fromscreeningtorandomization,26-weektreatmentperiod,and
1weekposttreatmentfollow-up).Thistreat-to-targettrialenrolled
adults (aged≥18years)with type2diabeteswithanHbA1c level
of7%to10%(inclusive),whoweretakingastabledoseofglargine
(totaldailydose,20-50U, inclusive,allowing individual fluctua-
tionsof±10%forat least56daysprior to screening),withstable
daily dosing of metformin (≥1500 mg or maximum tolerated
dose), bodymass index (BMI; calculatedasweight inkilograms
dividedbyheight inmeters squared)of40or lower, andable to
adhere to the protocol. The trial protocol and statistical analy-
sis plan are available in Supplement 1.
Interventions
Patients were randomized 1:1 via an interactive voice/web re-
sponse system to receive degludec/liraglutide or continued
glargine,eachtreatment titratedto thesamefastingglucose tar-
get. Patients randomized todegludec/liraglutidediscontinued
glargineand initiateddegludec/liraglutideat 16dosesteps (16U
of degludec/0.6 mg of liraglutide), irrespective of the dose of
glargine at the time of randomization, and dosed once daily at
anytimeofday,preferablyat thesametimeeveryday.Themaxi-
mum allowed dose was 50 dose steps providing 50 U of de-
gludec and 1.8mgof liraglutide (themaximumdose of liraglu-
tide approved for the type 2 diabetes indication).
Patients randomized toglargine continued treatmentwith
their pretrial dosing,with nomaximumdaily dose during the
trial period.Glarginewasdosedoncedaily according to the lo-
cally approved prescribing information.
Inbothgroups, target-driventitrationwasperformedtwice
weekly based on themean of 3 previous daily self-monitored
prebreakfast blood glucose measurements. If this mean was
above or below the 72 to 90mg/dL target (to convert glucose
to mmol/L, multiply by 0.0555), patients were to respec-
tively increase or decrease their dose by 2 dose steps or 2 U.
Main Outcomes andMeasures
The primary end point was change in HbA1c level from base-
line to26weeks. Secondaryendpointswerechange frombase-
line in body weight and number of treatment-emergent hy-
poglycemicepisodesduring26weeks.Exploratoryprespecified
endpoints included insulindose, change frombaseline in fast-
ing plasma glucose (FPG) level, 9-point self-measured blood
glucose (SMBG) profile, responders for HbA1c level (pre-
defined targets of <7.0% and ≤6.5%), and for composite tar-
gets based onHbA1c levelwithout hypoglycemia and/orwith-
out weight gain. Time points included in the 9-point SMBG
profile were breakfast, 90 minutes after breakfast, lunch, 90
minutes after lunch, dinner, 90 minutes after dinner, bed-
time, 4:00 AM, and breakfast the next day. Post-hoc analysis
ofmeanblood glucose at each timepoint in the9-point SMBG
profileandanalysisof confirmedhypoglycemiabyendof treat-
ment HbA1c level were also performed. Safety end points in-
cludednumberof treatment-emergentadverseeventsandnoc-
turnal hypoglycemic episodes during the 26-week treatment
period, change frombaseline in standard laboratory analyses
(including lipidprofile, amylase, lipase, andcalcitonin), blood
pressure, electrocardiogram, and pulse.
Confirmed hypoglycemic episodes were defined as epi-
sodes in which plasma glucose was biochemically confirmed
as less than 56mg/dL, with orwithout symptoms or inwhich
the patient required assistance. A hypoglycemic episode was
classified as severe if thepatient required assistance, andnoc-
turnal if it occurred between 12:01 AM and 05:59 AM (both in-
clusive). Patient-reportedoutcomesweremeasuredusing the
Treatment-Related ImpactMeasure forDiabetes (TRIM-D) and
36-Item Short Form Survey (SF-36).
ETD estimated treatment difference
FPG fasting plasma glucose
GLP-1RA glucagon-like peptide-1
receptor agonist
PYE patient-year of exposure
SMBG self-measured blood glucose
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Ethnicity and race were recorded to meet regulatory re-
quirements and were self-reported by the participant from a
predefined list.
All collected blood samples were processed and shipped
immediately to a central laboratory (Quintiles),where all para-
meters were analyzed.
Statistical Analysis
The trialwaspowered to theprimaryobjectiveof demonstrat-
ing noninferiority using a t test under the following assump-
tions:no treatmentdifference, anoninferioritymarginof0.3%,
1:1 randomization, nominal power of 90%, standard devia-
tionof 1%,and15%dropout.Thenoninferioritymarginof0.3%
was selected basedon existingUSFood andDrugAdministra-
tion (FDA) guidance, and is considered in the field the mini-
mal clinically significant change for HbA1c level.5
In total, 554patientswereplanned tobe randomized. The
primary end point was analyzed using a standard analysis of
covariance (ANCOVA)model, including treatment and region
as fixed factors and baseline HbA1c level as covariate. For sec-
ondary end points the family-wise type I errorwas controlled
using 1-sided testing at the 2.5% level using the followingpre-
specified testprocedure that combineshierarchical testingand
theHolm-Bonferronimethod.First, theprimaryendpointwas
tested fornoninferiorityusing 1-sided testingat the2.5% level.
Second, if statistical significance was obtained, testing pro-
ceeded (hierarchical part) to the secondaryendpoints. In turn,
these endpointswere testedby theHolm-Bonferronimethod
comparing 1-sidedPvaluesagainst 2.5%significance levels ad-
justed for multiplicity.6 Exploratory end points were tested
2-sided at the 5% level and not adjusted for multiplicity.
Continuous end points were analyzed by ANCOVA with
treatment and region as fixed factors and correspondingbase-
linevalueas covariate (plusbaselineHbA1c level fordose); fast-
ing lipid laboratory analyseswere log-transformedprior to the
analysis.The9-pointSMBGprofilevalueswereanalyzed jointly
using a linearmixed-modelwith anunstructured residual co-
variance matrix for measurements within patient and with
treatment, time point, region, and interaction between treat-
mentandtimepointas fixedeffectsandbaseline9-pointSMBG
profile values as covariates.Hypoglycemic episodeswere ana-
lyzed using a negative binomial regression model with a log-
link function and log of the exposure time as offset that in-
cluded treatment and region as fixed factors. Responder end
points (proportion of patients achieving HbA1c level <7.0%,
HbA1c level≤6.5%,andthecompositeendpointsdescribedpre-
viously) were analyzed by a generalized linearmodelwith bi-
nomial distribution and identity link that included treatment
as a fixed factor. The choice of ANCOVA for continuous end
pointswas based on EuropeanMedicines Agency (EMA)/FDA
guidance and wide acceptance, and the negative binomial
analysis of hypoglycemic events iswidely accepted for diabe-
tes trials.5,7,8 Models were checked by residual plots and di-
agnostic statistics. Statistical analyses were based on the full
Figure 1. Flow of Patients Through the DUAL V Trial
767 Patients screened for eligibility
557 Randomized
278 Randomized to receive insulin
degludec/liraglutide
278 Received insulin degludec/
liraglutide as randomized
279 Randomized to receive insulin
glargine
279 Received insulin glargine
as randomized
250 Completed the trial 265 Completed the trial
278 Included in the primary analysis 279 Included in the primary analysis
28 Withdrew
1 At the discretion of the investigator
5 Without explanation
1 Other
9 Adverse events
2 Nonadherence
1 Fasting SMBG or FPG exceeded the limit c
1 Repeated asymptomatic and/or
symptomatic hypoglycemia
8 Randomized in contravention of the
inclusion or exclusion criteria
14 Withdrew
1 Initiation of any systemic treatment b
4 Without explanation
1 Other
1 Adverse events
1 Nonadherence
1 Fasting SMBG or FPG exceeded the limit c
1 Repeated asymptomatic and/or
symptomatic hypoglycemia
4 Randomized in contravention of the
inclusion or exclusion criteria
210 Excluded (ineligible) a
168 Did not meet inclusion criteria
19 Impaired renal function
151 Did not meet glycated
hemoglobin criteria
43 Met exclusion criteria
16 Other reasons for ineligibility
FPG indicates fasting plasma glucose;
SMBG, self-measured blood glucose.
a Patients could havemore than 1
exclusion or inclusion criteria.
Details only provided for criteria
accounting for more than 5%
screening failure rate.
b Initiation of any systemic treatment
with products that, in the
investigator’s opinion, could
interfere with glucosemetabolism.
c Fasting SMBG or FPG limits leading
to withdrawal were 270mg/dL
(to convert FPG tommol/L, multiply
by 0.0555) from baseline to week 6,
240mg/dL fromweek 7 to week 12,
and 200mg/dL fromweek 13 to
week 26.
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analysis set (all randomizedpatients); efficacy and safety end
pointdescriptive statistics arebasedonthe full analysis set and
safety analysis set (all patients receiving at least 1 dose of trial
product), respectively (Figure 1). For the full analysis set analy-
ses anddescriptive statistics, a patient contributedwith treat-
ment“as randomized” (intention-to-treatprinciple).For safety
analysis set descriptive statistics, a patient contributed with
treatment“as treated” (principleof safetyattributable todrug).
In this particular trial, the 2 analysis sets are identical (ie, all
randomizedpatientswere exposed to their randomized treat-
ment).Data are reportedasmean (SD)unlessotherwisenoted.
The estimated treatment differences (ETD) were calculated
fromthepoint estimatesof the2 treatments fromtheANCOVA
model (treatment factor levels) and associated standard error
and covariance.
Sensitivity analyses were performed for secondary end
points. For continuous endpoints (HbA1c level andweight) re-
peated measures and 2 multiple imputation–based methods
with sequential ANCOVAs were conducted.9,10 Hypoglyce-
mic episodes were analyzed by multiple imputation method
using a posterior Bayesian approach.11
All statistical analyses were performed using SAS
(SAS Institute), version 9.3.
Results
Patient Population
Patients from 10 countrieswere included, 767were screened,
and 557 were randomized and exposed to the trial products
(Figure1) fromSeptember20,2013, throughNovember4,2014.
Of the557patients randomized (mean: age58.8years;women,
49.7%), 92.5% completed the trial and provided data at 26
weeks.The treatmentgroupswerecomparableatbaselinewith
respect todemographics and characteristics (Table 1). In total,
239 of 278 patients receiving degludec/liraglutide (86%) and
255of279patients receivingglargine (91%)attendedall sched-
uled visits fromweek 0 to 26.
Primary Objective
HbA1c level decreased from baseline for the degludec/
liraglutide group (8.4% [SD, 0.9%]) and glargine group (8.2%
[SD, 0.9%]) over the first 16weeks of treatment and stabilized
at 6.6% for thedegludec/liraglutide group (SD,0.9%) and7.1%
for the glargine group (SD, 0.9%) by week 26. After 26 weeks
of treatment,meanHbA1c level haddecreasedby 1.81% for the
degludec/liraglutide group (SD, 1.08%) and by 1.13% for the
glargine group (SD, 0.98%)with glargine corresponding to an
ETD of –0.59% (95% CI, –0.74% to –0.45%) (Table 2 and
Figure 2A), demonstrating noninferiority of degludec/
liraglutide (upper bound of the 95% CI, –0.45%; less than the
noninferiority margin of 0.3%, 1-sided P for noninferior-
ity < .001) compared with glargine.
Secondary End Points
The ETD for change in HbA1c level (–0.59% [95% CI, –0.74%
to –0.45%], 1-sided P < .001) also met criteria for statistical
superiority of degludec/liraglutide vs glargine (Table 2 and
Table 1. Baseline Demographics and Patient Characteristics of the Full
Analysis Set
Insulin Group, Mean (SD)
Degludec/
Liraglutide
(n = 278)
Glargine
(n = 279)
Women, No. (%) 135 (48.6) 142 (50.9)
Age, y 58.4 (9.8) 59.1 (9.3)
Race, No. (%)
White 262 (94.2) 265 (95.0)
Black or African American 6 (2.2) 5 (1.8)
Asian 9 (3.2) 9 (3.2)
Other 1 (0.4) 0 (0.0)
Ethnicity, No. (%)
Hispanic or Latino 107 (38.5) 133 (47.7)
Not Hispanic or Latino 171 (61.5) 146 (52.3)
Body weight, kg 88.3 (17.5) 87.3 (15.8)
BMI 31.7 (4.4) 31.7 (4.5)
Duration of diabetes, y 11.64 (7.44) 11.33 (6.59)
HbA1c, % 8.4 (0.9) 8.2 (0.9)
Fasting plasma glucose, mg/dL 160.5 (47.5) 159.8 (52.0)
Basal insulin dose at screening, U 31 (10) 32 (10)
Vital parameters
Pulse rate, beats/mina 74.9 (9.4) 74.0 (10.4)
Blood pressure, mm Hg
Systolic 133.0 (13.8) 129.3 (13.8)
Diastolic 79.4 (8.4) 78.7 (8.3)
Concomitant illnesses, No. (%)
Hypertension 209 (75.2) 194 (69.5)
Dyslipidemia 173 (62.2) 170 (60.9)
Laboratory measurements
Total cholesterol, mg/dL 181.4 (41.2) 180.6 (44.5)
LDL-C, mg/dL 101.6 (35.8) 98.1 (35.0)
Free fatty acids, mg/dL 15.0 (5.90) 14.1 (6.52)
HDL-C, mg/dL 46.5 (10.9) 47.0 (12.2)
VLDL-C, mg/dL 33.22 (17.39) 35.33 (30.40)
Triglycerides, median (range),
mg/dL
146.9
(36.3-1031.9)
140.7
(40.7-3790.3)
Lipase, U/L 41.7 (26.6) 43.3 (27.8)
Amylase, U/L 61.8 (43.0) 59.2 (29.1)
Calcitonin, median (range), pg/mL 1.0 (1.0-18.1) 1.0 (1.0-42.0)
Concomitant medication at screening,
No. (%)a
Statins 122 (43.9) 128 (45.9)
Fibrates 22 (7.9) 23 (8.2)
Other lipid-modifying drugs 5 (1.8) 4 (1.4)
Blockers of renin-angiotensin system 182 (65.5) 177 (63.4)
Calcium channel blockers 54 (19.4) 58 (20.8)
β-Blockers 74 (26.6) 83 (29.7)
Diuretics 25 (9.0) 19 (6.8)
Abbreviations: BMI, bodymass index (calculated as weight in kilograms
divided by height in meters squared); HbA1c, glycated hemoglobin;
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein
cholesterol; VLDL-C, very low–density lipoprotein cholesterol.
SI Conversion: To convert FPG tommol/L, multiply by 0.0555; total cholesterol,
HDL-C, and LDL-C tommol/L, multiply by 0.0259; fatty acids to mmol/L,
multiply by 0.0355; triglycerides to mmol/L, multiply by 0.0113; calcitonin to
pmol/L, multiply by 0.292; amylase and lipase to μkat/L, multiply by 0.0167.
a Data were based on the safety analysis set.
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Figure 2A). A reduction in body weight of 1.4 kg (SD, 3.5) was
observed in the degludec/liraglutide group from 88.3 kg (SD,
17.5) to 86.9 kg (SD, 17.2), whereas the glargine group had an
increase in body weight of 1.8 kg (SD, 3.6) from 87.3 kg (SD,
15.8) to 89.1 kg (SD, 15.9); ETD, –3.20 kg (95% CI, –3.77 to
–2.64), 1-sided P < .001 (Table 2 and Figure 2B). Confirmed
hypoglycemia occurred in fewer patients receiving degludec/
liraglutide than those receiving glargine (28.4% for the
degludec/liraglutide group and 49.1% for the glargine group),
with reduced rates of 2.23 episodes vs 5.05 episodes per
patient-year of exposure (PYE) (estimated rate ratio, 0.43
[95% CI, 0.30 to 0.61], 1-sided P < .001) (Table 2; Figure 2C).
One severe hypoglycemic episode was reported in the trial,
which was in the glargine group. Sensitivity analyses all dem-
onstrated similar results in terms of statistical significance
and effect sizes (eTable 1 in Supplement 2).
Exploratory Prespecified End Points
FPG levelhaddecreased inbothgroupsafter 26weeksof treat-
ment to 109.5 mg/dL (SD, 38.4) for the degludec/liraglutide
group and 110.2mg/dL (SD, 38.6) for the glargine group; ETD,
–0.15mg/dL (95%CI, –6.28 to 5.99),P = .96 (Figure 3A).Mean
SMBG levelsmeasured for dose adjustmentdecreased inboth
groups over the first 12 weeks (more rapidly with degludec/
liraglutide) and stabilized until week 26 at 105.8 mg/dL (SD,
26.0) for the degludec/liraglutide group and at 100.7 mg/dL
(SD, 23.7) for the glargine group, as expected in a treat-to-
target trial.
At week 26, the mean of the 9-point SMBG measure-
mentshaddecreased inboth groups, by45.6mg/dL (SD, 44.9)
from baseline to 136.5 mg/dL (SD, 34.6) at 26 weeks for de-
gludec/liraglutide and by 42.6 mg/dL (SD, 49.5) from base-
line to 141.4mg/dL (SD, 33.8) at 26weeks for glargine. The be-
tween-groupETDwas –4.0mg/dL (95%CI, –9.6 to 1.6),P = .16
(Figure 3B).
Morepatients randomizedtodegludec/liraglutideachieved
HbA1c targets (specifically, <7.0% as well as ≤6.5%) than with
glargine, and did so without weight gain and/or hypoglyce-
mia (P < .001 for all) (Table 3).
In the glargine group, 24.4% of patients reported noctur-
nal confirmed hypoglycemic episodes, as did 6.1% in the
degludec/liraglutidegroup,withevent ratesperPYEof 1.23 for
theglarginegroupand0.22 for thedegludec/liraglutidegroup.
The estimated rate ratio for nocturnal hypoglycemiawas 0.17
(95% CI, 0.10 to 0.31), P < .001 (Figure 3C).
After 26 weeks, there were increases in the mean daily
doseofdegludec/liraglutide to41dose steps (41Uofdegludec/
1.48 mg of liraglutide) (range, 16–50) and to 66 U for glargine
(range, 17–153) (Figure3D).Thebetween-groupETDinsulindose
was–25.47U(95%CI,–28.90to–22.05),P < .001.Approximately
40%of patients in the degludec/liraglutide group received the
maximum50dosestepsafter26weeks,ofwhich68%achieved
anHbA1c level lessthan7%comparedwith74%ofthosewhoused
less than themaximumallowed degludec/liraglutide dose.
Patient-Reported Outcomes
The physical component score of the SF-36 questionnaire
improved with degludec/liraglutide (from 47.4 [95% CI, 46.4
to 48.5] at baseline to 49.0 [95% CI, 48.0 to 50.0] at week 26)
and worsened with glargine (from 47.7 [95% CI, 46.7 to 48.7]
at baseline to 47.2 [95% CI, 46.1 to 48.3] at week 26); ETD, 1.9
[95% CI, 0.8 to 3.1], P < .001 (eTable 2 in Supplement 2). This
was also the case with physical functioning (ETD, 1.4 [95%
CI, 0.0 to 2.7], P = .045) and bodily pain (ETD, 2.0 [95% CI,
0.4 to 3.6], P = .01) subdomains; the general health subdo-
main score increased more with degludec/liraglutide (from
42.9 [95% CI, 41.9 to 44.0] at baseline to 46.2 [95% CI, 45.2 to
47.3] at week 26) than with glargine (from 43.6 [95% CI, 42.5
to 44.7] at baseline to 45.0 [95% CI, 43.9 to 46.1] at week 26;
ETD, 1.7 [95%CI,0.4 to2.9],P = .008). Therewasnobetween-
group difference in overall mental score (ETD, –0.1 [95% CI,
–1.5 to 1.3], P = .93) or any component subdomains. Patient-
reportedoutcome scores using theTRIM-Dquestionnaire im-
proved inall subdomainsand in total score inbothgroups.The
increase in total score was greater with degludec/liraglutide
(from 74.6 [95% CI, 73.1 to 76.2] at baseline to 82.1 [95% CI,
80.6 to 83.7] at week 26) compared with glargine (from 73.6
[95%CI, 72.1 to 75.1] at baseline to 78.9 [95%CI, 77.4 to 80.4]
at week 26; ETD, 2.8 [95% CI, 0.9 to 4.7], P = .003), largely
drivenbyhigher scores than glargine in the treatment burden
(ETD, 3.7 [95% CI, 0.7 to 6.8], P = .02) and diabetes manage-
ment (ETD, 7.2 [95% CI, 4.2 to 10.2], P < .001) subdomains,
indicating higher treatment satisfaction with degludec/
liraglutide (eTable 2 in Supplement 2).
Table 2. Summary of Primary and Secondary End Points for Degludec/Liraglutide vs Glargine
End Point
Insulin Group
Degludec/Liraglutide vs
Glarginea 1-Sided P Value
Degludec/
Liraglutide
(n = 278)
Glargine
(n = 279)
HbA1c level at week 26, % 6.6 7.1
Change from baseline
in HbA1c level, % (95% CI)
−1.81
(−1.94 to −1.68)
−1.13
(−1.25 to −1.02)
ETD (95% CI): −0.59
(−0.74 to −0.45)
Noninferiority:
<.001
Superiority:
<.001
Body weight at week 26, kg 86.9 89.1
Change from baseline,
body weight, kg (95% CI)
−1.4
(−1.8 to −1.0)
1.8
(1.4 to 2.2)
ETD (95% CI): −3.20
(−3.77 to −2.64)
Superiority:
<.001
Total exposure, y 129.6 135.1
Rate of confirmed hypoglycemia,
no. of events per PYE
2.23 5.05 ERR (95% CI): 0.43
(0.30 to 0.61)
Superiority:
<.001
Abbreviations: ERR, estimated rate
ratio; ETD, estimated treatment
difference; HbA1c, glycated
hemoglobin; PYE, patient-year of
exposure.
a The ETDwas estimated from an
analysis of covariance analysis
based on the full analysis set. The
ERRwas the ETD of the linear
predictor of a negative binomial
regressionmodel, back transformed
to event per time scale, based on
the full analysis set.
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Post Hoc Analyses
The lower rate of confirmed hypoglycemia observed with
degludec/liraglutide compared with glargine was also seen
irrespectiveof end-of-trialHbA1c level (eFigure 1 inSupplement
2). Post hoc analysis of the 9-point SMBG measurements,
using a linear mixed-model, showed a statistically signifi-
cantly lower blood glucose level 90 minutes after lunch
(ETD, –11.54 mg/dL [95% CI, –19.83 to –3.25], P = .006),
before dinner (ETD, –12.48 mg/dL [95% CI, –20.05 to –4.92],
P = .001), and after dinner (ETD, –10.24 mg/dL [95% CI,
–19.45 to –1.02], P = .03), but a higher blood glucose level
before breakfast (ETD, 8.28 mg/dL [95% CI, 2.98 to 13.59],
P = .002) and before breakfast on the following day (ETD,
7.23 mg/dL [95% CI, 1.42 to 13.04], P = .02) for degludec/
liraglutide than with glargine; blood glucose levels were
similar at the other 4 time points.
Figure 2. Change in HbA1c Levels and BodyWeight, and Cumulative Incidence of ConfirmedHypoglycemia Over
Time for Degludec/Liraglutide vs Glargine
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Vital Parameters
After 26 weeks of treatment, heart rate increased in the de-
gludec/liraglutidegroupand remainedsimilar tobaselinewith
glargine (ETD, 3.71 beats/min [95%CI, 2.33 to 5.08],P < .001).
Systolic blood pressure decreased with degludec/liraglutide
and remained unchanged with glargine (ETD, –3.57 mm Hg
[95% CI, –5.54 to –1.59], P < .001). There was no difference in
the change in diastolic blood pressure between the groups
(ETD, 0.91 mmHg [95% CI, –0.28 to 2.10], P = .14), which re-
mained similar to baseline (eTable 3 in Supplement 2).
LaboratoryMeasurements
After 26 weeks of treatment, total cholesterol (estimated
treatment ratio [ETR], 0.95 [95% CI, 0.92 to 0.98], P <.001),
low-density lipoprotein cholesterol (ETR, 0.92 [95% CI,
0.88 to 0.97], P <.001) and free fatty acids (ETR, 0.85 [95%
CI, 0.80 to 0.92], P <.001) were lower with degludec/
liraglutide than with glargine. No differences were
observed for high-density lipoprotein, very low–density
lipoprotein, and triglycerides between the groups at the end
of trial.
Figure 3. Change in Fasting Plasma Glucose, 9-Point SMBG Profile, Nocturnal Hypoglycemia, and Insulin Dose Over Time
for Degludec/Liraglutide vs Glargine
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There were increases in mean lipase (17.6 U/L [SD, 37.0];
to convert toμkat/L,multiplyby0.0167) andamylase (10.7U/L
[SD,22.1]; toconvert toμkat/L,multiplyby0.0167)activitydur-
ing the treatmentperiod in thedegludec/liraglutidegroupand
minimal change in the glargine group (–2.2 U/L [SD, 29.2] for
lipase and 2.2 U/L [SD, 18.4] for amylase).
Calcitonin levels were similar between the degludec/
liraglutide and glargine groups throughout the trial and there
was no clinically relevant change from baseline at week 26 in
either group:median change frombaseline0.0pg/mL (range,
–3.4-47.7) for the degludec/liraglutide group and 0.0 pg/mL
(range, –20.5-8.0) for theglarginegroup (to convert topmol/L,
multiply by 0.292).
Adverse Events
The overall rate of adverse events per 100 PYE was 343.3 for
thedegludec/liraglutidegroupand286.4for theglarginegroup.
Serious adverse events per 100PYEwere 3.9 for thedegludec/
liraglutide group and 6.7 for the glargine group. Themajority
of adverse eventsweremild and judged to be unlikely related
to the trial products by the investigator. A higher proportion
of adverse events were judged related to the trial product in
the degludec/liraglutide group, these were mainly gastroin-
testinal disorders. Accordingly, nauseawas reported bymore
patients in the degludec/liraglutide group (9.4%; n = 26; 26.2
events per 100 PYE) than the glargine group (1.1%; n = 3; 2.2
events per 100 PYE). However, no more than 4% of patients
experienced nausea with degludec/liraglutide at any given
week during the trial (eFigure 2 in Supplement 2).
Of5cardiovasculareventssent foradjudication,4werecon-
firmed by the external blinded event adjudication committee,
2ofwhichweremajor cardiovascular events (definedasnonfa-
tal myocardial infarction, nonfatal stroke, or cardiovascular
death) (1 in each group). A patient treatedwith glargine died of
hemorrhagic stroke, and a patient treated with degludec/
liraglutidehadanischemicstrokefollowedbyfull recovery.Both
eventswere considered unlikely related to the trial product by
the investigator. Sevenpotential eventsofneoplasmwere sent
totheeventadjudicationcommitteeforadjudication;3werecon-
firmed(rectal adenocarcinoma,prostatecancer, andmetastatic
pancreaticcarcinoma; the latterdiagnosed9daysafterstopping
treatment [day 54 of the trial]), all in the degludec/liraglutide
groupandall consideredunlikely related to the trial productby
the investigator.Twothyroiddiseaseeventsweresent foradju-
dication; neither were confirmed as thyroid neoplasms. The
single event of pancreatitis sent for adjudication was not con-
firmed by the event adjudication committee.
Discussion
Amongpatientswithuncontrolled type2diabetes treatedwith
glargine andmetformin, degludec/liraglutide achievednonin-
ferior HbA1c level reduction (primary objective), and subse-
quently statistically greater HbA1c level reduction (secondary
objective) compared with continued glargine titration, when
both products were titrated to the same fasting glycemic tar-
get. Further analyses demonstrated that degludec/liraglutide
wasassociatedwithweight losscomparedwithweightgainwith
glargine and a lower rate of hypoglycemia.
Despite the initial reduction in insulin dose for patients
randomized to the degludec/liraglutide group, from a mean
of 31 U to 16 dose steps (including a liraglutide component of
0.6 mg), there was no deterioration in mean SMBGmeasure-
ment immediately following this switch. The mean SMBG
measurement decrease following randomization was greater
in the degludec/liraglutide group, indicating a faster thera-
peutic response to degludec/liraglutide initiation compared
with glargine up-titration. The maximum allowed dose of
degludec/liraglutidewas 50dose steps,whereas therewasno
predefinedmaximumdaily dose of glargine. Despite the dos-
ing cap, a statistically andclinically significantly greaterHbA1c
level reductionwasachieved in thedegludec/liraglutidegroup
compared with the glargine group (final dose 41 U in the
degludec/liraglutide groupvs66U in the glargine group). The
majority of patients treatedwithdegludec/liraglutidemet the
less than 7.0%and6.5%or lessHbA1c level targets,more than
those in the glargine group, with a lower rate of hypoglyce-
mia. These findings highlight the therapeutic benefits of the
liraglutide component and its insulin-sparing effect.
The combination of basal insulin and GLP-1RA as a treat-
ment option is well established.3,12 Concern about hypogly-
cemia is a barrier to good glycemic control, rendering pa-
tients unwilling to optimize treatment with insulin13 and
clinicians reticent to recommend more aggressive treatment
targets.14 The burden of treatment complexity13,14 and con-
Table 3. Proportion of Patients Achieving HbA1c and Composite Targets
Insulin, No. (%)a
Between-Group Treatment
Difference, % (95% CI)b P Value
Degludec/
Liraglutide Glargine
HbA1c level <7% 199 (71.6) 131 (47.0) 24.6 (16.7-32.5) <.001
No weight gain 139 (50.0) 55 (19.7) 30.3 (22.8-37.8) <.001
No hypoglycemic episodes 151 (54.3) 82 (29.4) 24.9 (17.0-32.9) <.001
No weight gain,
no hypoglycemic episodes
108 (38.8) 34 (12.2) 26.7 (19.8-33.6) <.001
HbA1c level ≤6.5% 154 (55.4) 86 (30.8) 24.6 (16.6-32.5) <.001
No weight gain 116 (41.7) 35 (12.5) 29.2 (22.2-36.2) <.001
No hypoglycemic episodes 115 (41.4) 53 (19.0) 22.4 (15.0-29.8) <.001
No weight gain,
no hypoglycemic episodes
88 (31.7) 21 (7.5) 24.1 (17.8-30.4) <.001
Abbreviations: HbA1c, glycated
hemoglobin.
a Responders were based on the full
analysis set and last observation
carried forward imputed data.
b Treatment differences were from a
generalized linear model with
binomial distribution and identity
link and treatment as a factor.
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cerns about weight gain15 may contribute to poor patient ad-
herence to treatment intensification.16Equally, physicians cite
lack of experience and time to educate patients as a barrier to
initiating,modifying, and intensifying insulin treatment.17 As
a once daily, single injection that is effective, associatedwith
weight loss, and a low risk of hypoglycemia, degludec/
liraglutidemayovercomemanyof thebarriers to treatment in-
tensification in patients treated with basal insulin. This sug-
gestion is supportedby thepatient-reportedoutcome results.
Gastrointestinal complicationsarewell-knownadverseef-
fects of treatment with GLP-1RA.18 In the liraglutide clinical
development program, nauseawas reported by between 14%
and 40%of patients treatedwith 1.2mg and 1.8mg of liraglu-
tide compared with glargine and placebo.19,20 In this trial, a
lower proportion of patients treated with degludec/
liraglutide reported 1 ormore episodes of nausea (9.4%). This
is likely due to amore gradual titration regimen for degludec/
liraglutide compared with that customarily used for liraglu-
tide (0.6mgweekly). The liraglutide component in degludec/
liraglutide isup-titrated in smaller increments (up to0.072mg
twiceweekly)with the titration schemeused, contributing to
the tolerability of the product. The open-label nature of this
trial could have introduced an unconscious bias resulting in
overreporting of these events, as even fewer patients re-
ported nausea (6.5%) in a double-blinded trial comparing
degludec/liraglutide with insulin degludec.21
This study had several important limitations. It was nec-
essary to perform the trial with an open-label design as the
maximumdoseof degludec/liraglutidewas 50dose steps and
otherwise a double-dummy design would have been re-
quired with patients administering 2 injections daily in unla-
beled syringes. The open-label nature of the trial may have
biased reporting of adverse events by investigators or patient-
reportedoutcomesscoringbypatients.However, theeventad-
judication committee, who adjudicated cardiovascular, neo-
plasm, thyroid disease, or pancreatitis eventswere blinded to
randomized treatment. The clinical applicability of this trial
is limited to those who fit the inclusion and exclusion crite-
ria. In clinical practice, this means that care must be taken to
avoid extrapolating expectations from these results to pa-
tients with diabetes who were, for example, previously un-
controlled on ahigher dose of basal insulin (ie, >50U) or basal
insulin in combination with therapies other thanmetformin.
Though the fastingglucose level achievedbystudyend is simi-
larbetweengroupsandtoother treat to target trials andthough
thedifferences of rates of hypoglycemiawere substantial, the
mean glargine dose did not reach a plateau at study end; this
does raise the possibility that with longer treatment duration
or alternative insulin regimensdifferences inHbA1c levelmay
have been minimized, but at the expense of greater differ-
ences in hypoglycemia and weight gain.
Further research is indicated to evaluate the durability of
the effects of degludec/liraglutide in longer-term studies, in
clinical practice, and to assess whether patients and physi-
cians consider degludec/liraglutide a suitable treatment op-
tion to overcome barriers to treatment intensification.
Conclusions
Among patients with uncontrolled type 2 diabetes taking
glargine andmetformin, treatmentwith degludec/liraglutide
compared with up-titration of glargine resulted in noninfe-
rior HbA1c levels, with secondary analyses indicating greater
HbA1c level reductionafter26weeksof treatment.Furtherstud-
ies are needed to assess longer-term efficacy and safety.
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